Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2
Ces deux études présentent la mise à jour des recommandations de l'"American Society of Clinical Oncology" concernant les traitements systémiques d'un cancer du poumon non à petites cellules de stade IV, avec et sans altérations génétiques "conductrices"
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See Appendix 1 (online only) for disclaimers and other important information. Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline.
In 2022, ASCO launched living clinical practice guidelines for systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) with1 and without driver alterations.2 Based on new evidence, this version of the stage IV NSCLC with driver alterations living guideline reviews evidence and provides updated recommendations on human epidermal growth factor receptor 2 (HER2; ERBB2) and KRAS G12C mutations. Appendix Table A2 (online only) provides all recommendations, and Appendix Figure A1 (online only) shows the updated algorithm for second- and third-line therapies. The ASCO Guidelines Methodology Manual (available at www.asco.org/guideline-methodology) and Supplement provide additional information.
Journal of Clinical Oncology , article en libre accès, 2021